15/12/20 AMAG Pharmaceuticals : Files Submission in Response to the Food and Drug Administration's Notice of Opportunity for a Hearing and Proposal to Withdraw Approval of Makena AQ
14/12/20 AMAG Pharmaceuticals : Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) PU
17/11/20 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
17/11/20 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
16/11/20 AMAG Pharmaceuticals : Covis Group Completes Acquisition of AMAG Pharmaceuticals AQ
Manager TitleAgeSince
Director of Finance/CFO - -
President 52 -
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member 52 -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
11/16/20 A Issuer sale

Chief Executive Officer

1,000,000 2.8983%
11/16/20 A Issuer sale

Director

118,526 0.3435%
11/16/20 A Issuer sale

Director

64,764 0.1877%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+0.29% - - 477M
+1.08%-3.84%+51.50%+160.13% 1,031B
+1.19%-5.10%+61.09%+56.36% 595B
+4.21%+0.65%+36.48%+87.04% 431B
+0.42%-0.99%+30.04%+22.27% 326B
+1.03%-2.10%+28.32%+45.08% 277B
+0.49%-11.32%+20.31%+22.32% 263B
+1.59%+3.91%-22.47%-36.84% 224B
+3.70%+0.98%+27.03%+63.38% 193B
+3.49%+0.35%+24.98%+76.58% 164B
Average +1.54%-3.79%+28.59%+55.15% 389.37B
Weighted average by Cap. +1.64%-4.31%+37.79%+79.43%
Logo AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
Employees
-
  1. Stock Market
  2. Stocks
  3. AMAG Stock